TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Aug 10, 2021 12:53 JST
Source:
Apollomics, Inc.
Apollomics, Inc. Doses First Patient in a Phase I Clinical Trial of APL-102
Foster City, CA, Hangzhou and Shanghai, China, Aug 10, 2021 - (ACN Newswire) - Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination oncology therapies, today announced the successful dosing of the first patient in a Phase I clinical study of APL-102 in patients with advanced solid tumors. The Phase I trial is designed to assess the safety, tolerability and pharmacokinetics of APL-102 delivered via an oral capsule.
"APL-102 is an internally discovered and developed tyrosine kinase inhibitor targeting multiple oncogenic drivers, and we are excited about advancing it for clinical testing to explore its potential for treating a number of solid tumors;" said Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer. "APL-102 is the first of several novel assets planned for clinical development to further expand Apollomics' clinical pipeline in oncology."
About APL-102
APL-102 is an oral, small molecule multi kinase inhibitor (MTKi) targeting several key oncogenic drivers. APL-102 inhibits several receptor tyrosine kinases (RTKs), including: angiogenesis via vascular endothelial growth factor receptors (VEGFRs), mitogen-activated protein kinase (MAPK) pathway via B-RAF and C-RAF; and colony stimulating factor 1 receptor (CSF1R).
Preclinical studies have demonstrated broad and potent antitumor activity in patient-derived xenograft mouse models of liver, breast, colorectal, gastric, esophageal and lung cancers. APL-102 has also shown favorable preclinical pharmacokinetic (PK) and safety profiles with no serious off-target activity observed. APL-102 has the potential to be used as a single agent or in combination with other oncology agents.
Apollomics retains worldwide rights to APL-102.
About Apollomics Inc.
Apollomics Inc. is an innovative biopharmaceutical company committed to the discovery and development of monotherapies and combination therapies of tumor-targeting agents and immuno-oncology agents. The Company's product pipeline has several programs at different stages of development, including novel, humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Apollomics has operating entities in Foster City, Ca., USA, Hangzhou and Shanghai, China. For more information, please visit www.apollomicsinc.com.
Contact information of Apollomics:
Investor Contact:
Wilson W. Cheung
Chief Financial Officer
(650) 209-4436
wcheung@apollomicsinc.com
U.S. Media Contact:
Remy Bernarda
Corporate Communications
(415) 203-6386
remy.bernarda@apollomicsinc.com
China Media Contact:
Porda Havas International Finance Communications Group
Kelly Fung
General Manager
(852) 3150 6763
kelly.fung@pordahavas.com
Phoenix Fung
Vice President
(852) 3150 6773
phoenix.fung@pordahavas.com
Source: Apollomics, Inc.
Sectors: Clinical Trials
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Related Press Release
Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq
March 30 2023 20:29 JST
Apollomics Inc. Expands Leadership Team with Appointment of Jane Wang, PhD as Chief Scientific Officer
July 26 2022 09:17 JST
Apollomics Inc. to Host Virtual Investor Events on Wednesday, January 26, 2022 and Thursday, January 27, 2022
January 12 2022 09:25 JST
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as Chairman of the Board for the BayHelix Group
January 04 2022 10:10 JST
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
November 22 2021 10:40 JST
Edison Oncology and Apollomics Announce Treatment of First Patient by EO1001 (APL-122) in a Phase I/IIa Clinical Trial
October 01 2021 10:00 JST
APOLLOMICS INC. ANNOUNCES OFFICIAL OPENING OF SHANGHAI BRANCH
May 20 2021 13:36 JST
Apollomics, Inc. Appoints Seasoned Healthcare Executive K. Peony Yu, M.D., as Chief Medical Officer
March 09 2021 10:35 JST
Apollomics, Inc Announces Enrollment of First Patient in Phase 1 Clinical Trial of APL-106 (uproleselan injection) in China
March 04 2021 11:30 JST
Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa
February 12 2021 13:00 JST
More Press release >>
Latest Press Release
Sumitomo Metal Mining and Mitsubishi Corporation to Participate in Kalgoorlie Nickel Project - Goongarrie Hub
Apr 30, 2024 19:08 JST
New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg
Apr 30, 2024 18:00 JST
Q&M Dental Enhances Digital Capabilities by Integrating Align Technology's Newest iTero Lumina(TM) Intraoral Scanner Across Dental Clinics in Singapore
Apr 30, 2024 17:25 JST
SPARX Group Establishes Space Frontiers Second Fund
Apr 29, 2024 18:49 JST
MHI Establishes Local Subsidiary "Mitsubishi Heavy Industries Vietnam"
Apr 29, 2024 18:00 JST
POSCO Future M and Honda Reach Basic Agreement on Collaboration for Production of Cathode Materials for Automotive Batteries in Canada
Apr 29, 2024 14:25 JST
Honda Plans to Establish Comprehensive Electric Vehicle Value Chain in Ontario, Canada
Apr 29, 2024 14:16 JST
JCB enables JCB Contactless acceptance at Taichung MRT in Taiwan
Apr 26, 2024 10:00 JST
Mazda Production and Sales Results for March 2024 and for April 2023 through March 2024
Apr 25, 2024 18:21 JST
MHI Begins Operation of SOEC Test Module the Next-Generation High-Efficiency Hydrogen Production Technology at Takasago Hydrogen Park
Apr 25, 2024 17:45 JST
GAC Honda to Begin Sales of All-new e:NP2, the Second Model of e:N Series
Apr 25, 2024 16:50 JST
Toyota Exhibiting at Beijing Motor Show 2024
Apr 25, 2024 16:25 JST
Honda Reaches Basic Agreement with Asahi Kasei on Collaboration for Production of Battery Separators for Automotive Batteries in Canada
Apr 25, 2024 11:10 JST
UNIQLO Sponsors KAWS + Warhol Exhibition Tour, Starting in Pittsburgh
Apr 25, 2024 09:00 JST
Mitsubishi Power Begins Commercial Operation of Seventh M701JAC Gas Turbine in Thailand GTCC Project; Achieves 75,000 AOH To-Date
Apr 24, 2024 17:19 JST
MC and Denka Sign J/V Agreement in Fullerene Business
Apr 24, 2024 17:02 JST
Mitsubishi Motors Posts Record Sales in the Philippines in FY2023
Apr 24, 2024 13:56 JST
NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance
Apr 24, 2024 13:25 JST
Fujitsu SX Survey reveals key success factors for sustainability
Apr 23, 2024 10:25 JST
Fujitsu and METRON collaborate to drive ESG success: slashing energy costs, boosting productivity with new manufacturing industry solutions
Apr 22, 2024 16:09 JST
More Latest Release >>